Burning Incense Is Psychoactive: New Class Of Antidepressants Might Be Right Under Our Noses

Religious leaders have contended for millennia that burning incense is good for the soul. Now, biologists have learned that it is good for our brains too. An international team of scientists, including researchers from Johns Hopkins University and the Hebrew University in Jerusalem, describe how burning frankincense (resin from the Boswellia plant) activates poorly understood ion channels in the brain to alleviate anxiety or depression. This suggests that an entirely new class of depression and anxiety drugs might be right under our noses.

"In spite of information stemming from ancient texts, constituents of Bosweilla had not been investigated for psychoactivity," said Raphael Mechoulam, one of the research study's co-authors. "We found that incensole acetate, a Boswellia resin constituent, when tested in mice lowers anxiety and causes antidepressive-like behavior. Apparently, most present day worshipers assume that incense burning has only a symbolic meaning."
To determine incense's psychoactive effects, the    researchers administered incensole acetate to mice. 

They found that the compound significantly affected areas in brain areas known to be involved in emotions as well as in nerve circuits that are affected by current anxiety and depression drugs. Specifically, incensole acetate activated a protein called TRPV3, which is present in mammalian brains and also known to play a role in the perception of warmth of the skin. When mice bred without this protein were exposed to incensole acetate, the compound had no effect on their brains.
"Perhaps Marx wasn't too wrong when he called religion the opium of the people: morphine comes from poppies, cannabinoids from marijuana, and LSD from mushrooms; each of these has been used in one or another religious ceremony." said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "Studies of how those psychoactive drugs work have helped us understand modern neurobiology. The discovery of how incensole acetate, purified from frankincense, works on specific targets in the brain should also help us understand diseases of the nervous system. This study also provides a biological explanation for millennia-old spiritual practices that have persisted across time, distance, culture, language, and religion--burning incense really does make you feel warm and tingly all over!"
According to the National Institutes of Health, major depressive disorder is the leading cause of disability in the United States for people ages 15--44, affecting approximately 14.8 million American adults. A less severe form of depression, dysthymic disorder, affects approximately 3.3 million American adults. Anxiety disorders affect 40 million American adults, and frequently co-occur with depressive disorders.

---

Story Source:
The above story is based on materials provided by Federation of American Societies for Experimental Biology. Note: Materials may be edited for content and length.

---

Journal Reference:

1. Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. Arieh Moussaieff, Neta Rimmerman, Tatiana Bregman, Alex Straiker, Christian C. Felder, Shai Shoham, Yoel Kashman, Susan M. Huang, Hyosang Lee, Esther Shohami, Ken Mackie, Michael J. Caterina, J. Michael Walker, Ester Fride, and Raphael Mechoulam. Published online before print May 20, 2008 as doi: 10.1096/fj.07-101865. [link]

Scientists discover how to 'switch off' autoimmune diseases

Scientists have made an important breakthrough in the fight against debilitating autoimmune diseases such as multiple sclerosis by revealing how to stop cells attacking healthy body tissue.

Date:

September 3, 2014

Source:

University of Bristol

Summary:

Scientists have made an important breakthrough in the fight against debilitating autoimmune diseases such as multiple sclerosis by revealing how to stop cells attacking healthy body tissue. Rather than the body's immune system destroying its own tissue by mistake, researchers have discovered how cells convert from being aggressive to actually protecting against disease.

Rather than the body's immune system destroying its own tissue by mistake, researchers at the University of Bristol have discovered how cells convert from being aggressive to actually protecting against disease.
The study, funded by the Wellcome Trust, is published in Nature Communications.

It's hoped this latest insight will lead to the widespread use of antigen-specific immunotherapy as a treatment for many autoimmune disorders, including multiple sclerosis (MS), type 1 diabetes, Graves' disease and systemic lupus erythematosus (SLE).
MS alone affects around 100,000 people in the UK and 2.5 million people worldwide.

Scientists were able to selectively target the cells that cause autoimmune disease by dampening down their aggression against the body's own tissues while converting them into cells capable of protecting against disease.
This type of conversion has been previously applied to allergies, known as 'allergic desensitisation', but its application to autoimmune diseases has only been appreciated recently.

The Bristol group has now revealed how the administration of fragments of the proteins that are normally the target for attack leads to correction of the autoimmune response.

Most importantly, their work reveals that effective treatment is achieved by gradually increasing the dose of antigenic fragment injected.
In order to figure out how this type of immunotherapy works, the scientists delved inside the immune cells themselves to see which genes and proteins were turned on or off by the treatment.

They found changes in gene expression that help explain how effective treatment leads to conversion of aggressor into protector cells. The outcome is to reinstate self-tolerance whereby an individual's immune system ignores its own tissues while remaining fully armed to protect against infection.
By specifically targeting the cells at fault, this immunotherapeutic approach avoids the need for the immune suppressive drugs associated with unacceptable side effects such as infections, development of tumours and disruption of natural regulatory mechanisms.

Professor David Wraith, who led the research, said: "Insight into the molecular basis of antigen-specific immunotherapy opens up exciting new opportunities to enhance the selectivity of the approach while providing valuable markers with which to measure effective treatment. These findings have important implications for the many patients suffering from autoimmune conditions that are currently difficult to treat."
This treatment approach, which could improve the lives of millions of people worldwide, is currently undergoing clinical development through biotechnology company Apitope, a spin-out from the University of Bristol.

---

Story Source:
The above story is based on materials provided by University of Bristol. Note: Materials may be edited for content and length. 
Also sciencedaily.com

---

Journal Reference:

1. Bronwen R. Burton, Graham J. Britton, Hai Fang, Johan Verhagen, Ben Smithers, Catherine A. Sabatos-Peyton, Laura J. Carney, Julian Gough, Stephan Strobel, David C. Wraith. Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nature Communications, 2014; 5: 4741 DOI: 10.1038/ncomms5741

Can Medical Marijuana reduce Opioid Overdose Mortality?

Can Medical Marijuana reduce Opioid Overdose Mortality?

  
 Reginald R Gervas, MD4.(MUHAS)

About one in every three individuals will experience chronic pain in their lifetime, and opioids are known to be an effective means to treat this condition.

The world (especially the developed countries) is faced with an increased bout in drug abuse and overdose deaths involving prescription opioid pain relievers such as morphine.
In USA, unintentional death from drug overdose have been increasing steeply from 1990s and they are the second leading cause of accidental deaths. The increase in death is caused by increase in opioids in managing chronic pain.

Due to urgency of this matter, there should be an alternative way in managing chronic pain rather than using opioids. Medical marijuana is one of good remedy in managing chronic pain. In states that have legalised medical marijuana, opioid overdose mortality has fallen impressively.

A study done by In an effort to examine the correlation between the presence of state medical cannabis laws and opioid analgesic overdose mortality, Marcus A. Bachhuber, MD et al performed a time-series analysis of medical cannabis laws and state-level death certificate data from 1999 to 2010 in all 50 states.

From the analysis, it has been shown that compared with states without medical cannabis laws, states with laws had a 24.8% lower mean annual opioid overdose mortality rate (P=0.003). In each year after implementation, these laws correlated with a lower rate of overdose mortality that generally strengthened over time (Table 1).

Years after medical cannabis law implementation	Change in overdose mortality
Year 1	-19.9%
Year 2	-25.2%
Year 3	−23.6%
Year 4	-20.2%
Year 5	−33.7%
Year 6	-33.3%

“Medical cannabis laws are associated with significantly lower state-level opioid overdose mortality rates. Further investigation is required to determine how medical cannabis laws may interact with policies aimed at preventing opioid analgesic overdose.” Wrote the researchers.

1. Schneider JP, Matthews M, Jamison RN (24 Oct 2010). "Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?". CNS Drugs 10 (80): 805–810 
2.  Okie S (November 2010). "A flood of opioids, a rising tide of deaths". N. Engl. J. Med. 363 (21): 1981–5. 
3.  Bachhuber M (august 2014). “Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010”. JAMA Intern Med

USAFIRI SIO ISHU

Natumaini umeshasikia majina kama usafiri,nyuma,kujazia,mnye,mkia na mengine mengi yakisifia makalio kwa wanawake.

Binafsi nimezoea kuona kua wanawake wana makalio makubwa zaidi ya wanaume na nimekua nikiamini ndio kawaida,hata tukiona mwanaume ana makalio makubwa huwa kama tunashangaa na kwake huwa ni kero, utafiti uliofanyika hivi karibuni huko ujerumani na Preininger B. et al katika pepa yao "The sex specificity of hip-joint muscles offers an explanation for better results in men after total hip arthroplasty" unaonesha kua wanaume ndio wana "ujazo mkubwa wa misuli ya makalio" kuliko wanawake.

Hii inaendana kabisa na ukweli kuwa wanaume huwa wana misuli mikubwa kuliko wanawake.

Je, kile tunachokiona kwa wanawake ni nini sasa? Hayo ni mafuta.

Katika kitabu kinachoitwa Text book of medical physiology kilichoandikwa na Arthur C.Guyton kinaeleza kuwa kuongezeka kwa kiasi cha mafuta mwilini kunapunguza usisimuliwaji wa seli na sukari kwenye damu,swala ambalo linapelekea kisukari,

sio tu hivyo,mafuta mengi mwilini huusishwa na magonjwa kama shinikizo la dam na saratani.Kuna haja ya kubadili mtazamo sasa, naamini hii inawezekana maana historia inatuambia mwanamke mzuri katika roma ya mwanzo alikua ni mwanamke mnene,ila leo huko magharibi mwanamke mnene ni kero. Wanaume wabadili tabia na wasiyaone makalio makubwa sana kama mazuri sana.

simaanishi wasiyaone makalio kama uzuri wa mwanamke hapana,makalio yanawafanya wanawake waonekane wazuri ila yasiwe malaini yenye mafuta mengi.

Wanawake wafanye mazoezi ili wapunguze mafuta na wakuze misuli ya makalio,hapo yatakua mazuri zaidi yenye kuvutia.

By Joseph Julius Masalu ( MD4,MUHAS)

Ebola outbreak: WHO warns that virus could infect 20,000

Bruce Aylward, a top WHO official, said the number of cases could be much higher than reported

 

The World Health Organization says the deadly Ebola outbreak in West Africa could infect more than 20,000 people before it is brought under control.

The UN agency said the number of cases could already be four times higher than the 3,000 currently registered.
It also called on airlines to resume "vital" flights across the region, saying travel bans were threatening efforts to beat the epidemic.
So far, 1,552 people in Liberia, Sierra Leone, Guinea and Nigeria have died.
Unprecedented scale Announcing a WHO action plan to deal with the outbreak, Bruce Aylward said "the actual number of cases may be 2-4 fold higher than that currently reported" in some areas.
The WHO assistant director-general said the possibility of 20,000 cases "is a scale that I think has not ever been anticipated in terms of an Ebola outbreak".
"That's not saying we expect 20,000... but we have got to have a system in place that we can deal with robust numbers," he added.
The WHO plan calls for $489 million (£295m) to be spent over the next nine months and requires 750 international workers and 12,000 national workers across West Africa.

On Thursday, Nigeria confirmed its first Ebola death outside Lagos, with an infected doctor in the oil hub of Port Harcourt dying from the disease.
Operations have not yet been affected in Africa's biggest oil producer, but a spokesman for Shell's Nigerian subsidiary said they were "monitoring the Ebola outbreak very closely".
Health ministers from across West Africa are meeting in Ghana at an extraordinary meeting of the Economic Community of West African States (Ecowas) to discuss how to prevent the virus from spreading further.
Officials at the Ecowas session backed the WHO's call for flight bans to be ended and called for states to reopen their borders to make it easier for health workers to access affected areas.

Earlier Mr Aylward insisted bans on travel and trade would not stop the spread of Ebola, saying they were "more likely to compromise the ability to respond".
Despite rumours to the contrary, the virus is not airborne and is spread by humans coming into contact with bodily fluids, such as sweat and blood, from those infected with virus.
The BBC's West Africa correspondent Thomas Fessy says medical agencies are struggling to cope with an increasing number of cases and growing hostility from communities in certain affected areas.
Efforts to prevent the virus spreading are unlikely to see any results given that most treatment centres are already operating at full capacity, our correspondent adds.
Meanwhile, British medical charity Wellcome Trust and pharmaceuticals giant GlaxoSmithKline (GSK) said safety trials on an experimental Ebola vaccine are being fast-tracked.
GSK says it plans to build up a stockpile of up to 10,000 doses for emergency deployment if results from the trials, which could begin as soon as next month, are good.

Ebola Virus Disease (EVD)

• Symptoms include high fever, bleeding and central nervous system damage
• Spread by body fluids, such as blood and saliva
• Fatality rate can reach 90% - but current outbreak has mortality rate of about 55%
• Incubation period is two to 21 days
• There is no vaccine or cure
• Supportive care such as rehydrating patients who have diarrhoea and vomiting can help recovery
• Fruit bats, a delicacy for some West Africans, are considered to be virus's natural host

What you need to know about ebola

Ebola virus disease

This information was taken from WHO 

---

Key facts

• Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever, is a severe, often fatal illness in humans.
• EVD outbreaks have a case fatality rate of up to 90%.
• EVD outbreaks occur primarily in remote villages in Central and West Africa, near tropical rainforests.
• The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission.
• Fruit bats of the Pteropodidae family are considered to be the natural host of the Ebola virus.
• Severely ill patients require intensive supportive care. No licensed specific treatment or vaccine is available for use in people or animals.

---

Ebola first appeared in 1976 in 2 simultaneous outbreaks, in Nzara, Sudan, and in Yambuku, Democratic Republic of Congo. The latter was in a village situated near the Ebola River, from which the disease takes its name.
Genus Ebolavirus is 1 of 3 members of the Filoviridae family (filovirus), along with genus Marburgvirus and genus Cuevavirus. Genus Ebolavirus comprises 5 distinct species:

• Bundibugyo ebolavirus (BDBV)
• Zaire ebolavirus (EBOV)
• Reston ebolavirus (RESTV)
• Sudan ebolavirus (SUDV)
• Taï Forest ebolavirus (TAFV).

BDBV, EBOV, and SUDV have been associated with large EVD outbreaks in Africa, whereas RESTV and TAFV have not. The RESTV species, found in Philippines and the People’s Republic of China, can infect humans, but no illness or death in humans from this species has been reported to date.

Transmission

Ebola is introduced into the human population through close contact with the blood, secretions, organs or other bodily fluids of infected animals. In Africa, infection has been documented through the handling of infected chimpanzees, gorillas, fruit bats, monkeys, forest antelope and porcupines found ill or dead or in the rainforest.
Ebola then spreads in the community through human-to-human transmission, with infection resulting from direct contact (through broken skin or mucous membranes) with the blood, secretions, organs or other bodily fluids of infected people, and indirect contact with environments contaminated with such fluids. Burial ceremonies in which mourners have direct contact with the body of the deceased person can also play a role in the transmission of Ebola. Men who have recovered from the disease can still transmit the virus through their semen for up to 7 weeks after recovery from illness.
Health-care workers have frequently been infected while treating patients with suspected or confirmed EVD. This has occurred through close contact with patients when infection control precautions are not strictly practiced.
Among workers in contact with monkeys or pigs infected with Reston ebolavirus, several infections have been documented in people who were clinically asymptomatic. Thus, RESTV appears less capable of causing disease in humans than other Ebola species.
However, the only available evidence available comes from healthy adult males. It would be premature to extrapolate the health effects of the virus to all population groups, such as immuno-compromised persons, persons with underlying medical conditions, pregnant women and children. More studies of RESTV are needed before definitive conclusions can be drawn about the pathogenicity and virulence of this virus in humans.

Signs and symptoms

EVD is a severe acute viral illness often characterized by the sudden onset of fever, intense weakness, muscle pain, headache and sore throat. This is followed by vomiting, diarrhoea, rash, impaired kidney and liver function, and in some cases, both internal and external bleeding. Laboratory findings include low white blood cell and platelet counts and elevated liver enzymes.
People are infectious as long as their blood and secretions contain the virus. Ebola virus was isolated from semen 61 days after onset of illness in a man who was infected in a laboratory.
The incubation period, that is, the time interval from infection with the virus to onset of symptoms, is 2 to 21 days.

Diagnosis

Other diseases that should be ruled out before a diagnosis of EVD can be made include: malaria, typhoid fever, shigellosis, cholera, leptospirosis, plague, rickettsiosis, relapsing fever, meningitis, hepatitis and other viral haemorrhagic fevers.
Ebola virus infections can be diagnosed definitively in a laboratory through several types of tests:

• antibody-capture enzyme-linked immunosorbent assay (ELISA)
• antigen detection tests
• serum neutralization test
• reverse transcriptase polymerase chain reaction (RT-PCR) assay
• electron microscopy
• virus isolation by cell culture.

Samples from patients are an extreme biohazard risk; testing should be conducted under maximum biological containment conditions.

Vaccine and treatment

No licensed vaccine for EVD is available. Several vaccines are being tested, but none are available for clinical use.
Severely ill patients require intensive supportive care. Patients are frequently dehydrated and require oral rehydration with solutions containing electrolytes or intravenous fluids.
No specific treatment is available. New drug therapies are being evaluated.

Natural host of Ebola virus

In Africa, fruit bats, particularly species of the genera Hypsignathus monstrosus, Epomops franqueti and Myonycteris torquata, are considered possible natural hosts for Ebola virus. As a result, the geographic distribution of Ebolaviruses may overlap with the range of the fruit bats.

Ebola virus in animals

Although non-human primates have been a source of infection for humans, they are not thought to be the reservoir but rather an accidental host like human beings. Since 1994, Ebola outbreaks from the EBOV and TAFV species have been observed in chimpanzees and gorillas.
RESTV has caused severe EVD outbreaks in macaque monkeys (Macaca fascicularis) farmed in Philippines and detected in monkeys imported into the USA in 1989, 1990 and 1996, and in monkeys imported to Italy from Philippines in 1992.
Since 2008, RESTV viruses have been detected during several outbreaks of a deadly disease in pigs in People’s Republic of China and Philippines. Asymptomatic infection in pigs has been reported and experimental inoculations have shown that RESTV cannot cause disease in pigs.

Prevention and control

Controlling Reston ebolavirus in domestic animals

No animal vaccine against RESTV is available. Routine cleaning and disinfection of pig or monkey farms (with sodium hypochlorite or other detergents) should be effective in inactivating the virus.
If an outbreak is suspected, the premises should be quarantined immediately. Culling of infected animals, with close supervision of burial or incineration of carcasses, may be necessary to reduce the risk of animal-to-human transmission. Restricting or banning the movement of animals from infected farms to other areas can reduce the spread of the disease.
As RESTV outbreaks in pigs and monkeys have preceded human infections, the establishment of an active animal health surveillance system to detect new cases is essential in providing early warning for veterinary and human public health authorities.

Reducing the risk of Ebola infection in people

In the absence of effective treatment and a human vaccine, raising awareness of the risk factors for Ebola infection and the protective measures individuals can take is the only way to reduce human infection and death.
In Africa, during EVD outbreaks, educational public health messages for risk reduction should focus on several factors:

• Reducing the risk of wildlife-to-human transmission from contact with infected fruit bats or monkeys/apes and the consumption of their raw meat. Animals should be handled with gloves and other appropriate protective clothing. Animal products (blood and meat) should be thoroughly cooked before consumption.
• Reducing the risk of human-to-human transmission in the community arising from direct or close contact with infected patients, particularly with their bodily fluids. Close physical contact with Ebola patients should be avoided. Gloves and appropriate personal protective equipment should be worn when taking care of ill patients at home. Regular hand washing is required after visiting patients in hospital, as well as after taking care of patients at home.
• Communities affected by Ebola should inform the population about the nature of the disease and about outbreak containment measures, including burial of the dead. People who have died from Ebola should be promptly and safely buried.

Pig farms in Africa can play a role in the amplification of infection because of the presence of fruit bats on these farms. Appropriate biosecurity measures should be in place to limit transmission. For RESTV, educational public health messages should focus on reducing the risk of pig-to-human transmission as a result of unsafe animal husbandry and slaughtering practices, and unsafe consumption of fresh blood, raw milk or animal tissue. Gloves and other appropriate protective clothing should be worn when handling sick animals or their tissues and when slaughtering animals. In regions where RESTV has been reported in pigs, all animal products (blood, meat and milk) should be thoroughly cooked before eating.

Controlling infection in health-care settings

Human-to-human transmission of the Ebola virus is primarily associated with direct or indirect contact with blood and body fluids. Transmission to health-care workers has been reported when appropriate infection control measures have not been observed.
It is not always possible to identify patients with EBV early because initial symptoms may be non-specific. For this reason, it is important that health-care workers apply standard precautions consistently with all patients – regardless of their diagnosis – in all work practices at all times. These include basic hand hygiene, respiratory hygiene, the use of personal protective equipment (according to the risk of splashes or other contact with infected materials), safe injection practices and safe burial practices.
Health-care workers caring for patients with suspected or confirmed Ebola virus should apply, in addition to standard precautions, other infection control measures to avoid any exposure to the patient’s blood and body fluids and direct unprotected contact with the possibly contaminated environment. When in close contact (within 1 metre) of patients with EBV, health-care workers should wear face protection (a face shield or a medical mask and goggles), a clean, non-sterile long-sleeved gown, and gloves (sterile gloves for some procedures).
Laboratory workers are also at risk. Samples taken from suspected human and animal Ebola cases for diagnosis should be handled by trained staff and processed in suitably equipped laboratories.

WHO response

WHO provides expertise and documentation to support disease investigation and control.
Recommendations for infection control while providing care to patients with suspected or confirmed Ebola haemorrhagic fever are provided in: Interim infection control recommendations for care of patients with suspected or confirmed Filovirus (Ebola, Marburg) haemorrhagic fever, March 2008. This document is currently being updated.
WHO has created an aide–memoire on standard precautions in health care (currently being updated). Standard precautions are meant to reduce the risk of transmission of bloodborne and other pathogens. If universally applied, the precautions would help prevent most transmission through exposure to blood and body fluids.
Standard precautions are recommended in the care and treatment of all patients regardless of their perceived or confirmed infectious status. They include the basic level of infection control—hand hygiene, use of personal protective equipment to avoid direct contact with blood and body fluids, prevention of needle stick and injuries from other sharp instruments, and a set of environmental controls.

Table: Chronology of previous Ebola virus disease outbreaks

Year	Country	Ebolavirus species	Cases	Deaths	Case fatality
2012	Democratic Republic of Congo	Bundibugyo	57	29	51%
2012	Uganda	Sudan	7	4	57%
2012	Uganda	Sudan	24	17	71%
2011	Uganda	Sudan	1	1	100%
2008	Democratic Republic of Congo	Zaire	32	14	44%
2007	Uganda	Bundibugyo	149	37	25%
2007	Democratic Republic of Congo	Zaire	264	187	71%
2005	Congo	Zaire	12	10	83%
2004	Sudan	Sudan	17	7	41%
2003 (Nov-Dec)	Congo	Zaire	35	29	83%
2003 (Jan-Apr)	Congo	Zaire	143	128	90%
2001-2002	Congo	Zaire	59	44	75%
2001-2002	Gabon	Zaire	65	53	82%
2000	Uganda	Sudan	425	224	53%
1996	South Africa (ex-Gabon)	Zaire	1	1	100%
1996 (Jul-Dec)	Gabon	Zaire	60	45	75%
1996 (Jan-Apr)	Gabon	Zaire	31	21	68%
1995	Democratic Republic of Congo	Zaire	315	254	81%
1994	Cote d'Ivoire	Taï Forest	1	0	0%
1994	Gabon	Zaire	52	31	60%
1979	Sudan	Sudan	34	22	65%
1977	Democratic Republic of Congo	Zaire	1	1	100%
1976	Sudan	Sudan	284	151	53%
1976	Democratic Republic of Congo	Zaire	318	280	88%